caa a22 4500 388097965 CHVBK 20180307125308.0 cr unu---uuuuu 161130e199906 xx s 000 0 eng 10.1017/S1121189X00000993 doi S1121189X00000993 pii (NATIONALLICENCE)cambridge-10.1017/S1121189X00000993 Drug attitude and subjective well-being in antipsychotic treatment monotherapy in real-world settings [Elektronische Daten] Aims - To assess using two well-know scales (DAI-30 and SWN) the drug attitude and subjective well-being of patients treated with haloperidol or second-generation antipsychotics (SGA) in four different Italian communities. Methods - The sample included 145 patients taking five different antipsychotics (APs) in mono-therapy: haloperidol, clozapine, olanzapine, risperidone, quetiapine. A stepwise multiple regression analysis (SMRA) was used to analyse the contribution of different AP treatments and of other predictors to SWN and DAI-30 scores. Results - Univariate analyses showed no differences in DAI-30 and SWN scores across treatments. The SMRA showed that SWN scores were negatively correlated with the severity of the psychoses (BPRS scores), while the DAI-30 scores were negatively correlated with the severity of the psychoses and positively correlated both with the length of drug treatment and with the use of olanzapine. Conclusions - Our study does not confirm a better drug attitude in patients treated with SGA with respect to haloperidol. The only partial exception is the better performance of olanzapine over haloperidol on DAI-30, which could be due to the lower use of anticholinergic drugs during olanzapine treatment. The differences between the SWN and DAI-30 may give good reason for the use of both instruments during AP treatments. Declaration of Interest: No grants have been received for this study. In the last two years: Matteo Balestrieri has received grants from AstraZeneca, Eli Lilly, BMS, Janssen-Cilag, Boehringer-Ingelheim, Innova-Pharma, Pfizer, Bristol, Abbott, Lundbeck; Guido Di Sciascio has received grants from AstraZeneca, Eli Lilly, BMS, Janssen-Cilag, Sanofi-Aventis, Wyeth, Boehringer- Ingelheim; Elisa Maso has received grants from Pfizer; Cesario Bellantuono has received grants from Eli Lilly, BMS, Boehringer- Ingelheim, Innova-Pharma, Italfarmaco; The other authors have not received any grants in the last two years. Copyright © Cambridge University Press 1999 drug attitude nationallicence subjective well-being nationallicence antipsychotic drugs nationallicence naturalistic study nationallicence Balestrieri Matteo Clinica di Psichiatria, Inter-University Centre for Behavioural Neurosciences, DPMSC, University of Udine, Udine Sciascio Guido Di Azienda Universitaria Ospedale Policlinico, Bari Isola Miriam Dipartimento di Ricerche Mediche e Morfologiche, University of Udine, Udine Lomonaco Emanuele Struttura Complessa di Psichiatria, Dipartimento di Salute Mentale, ASL 12 Biella Maso Elisa Clinica di Psichiatria, Inter-University Centre for Behavioural Neurosciences, DPMSC, University of Udine, Udine Merli Roberto Struttura Complessa di Psichiatria, Dipartimento di Salute Mentale, ASL 12 Biella Calò Salvatore Azienda Universitaria Ospedale Policlinico, Bari Bellantuono Cesario Sezione di Psichiatria, Dipartimento di Neuroscienze, Università Politecnica delle Marche, Ancona Epidemiologia e Psichiatria Sociale Cambridge University Press 18/2(1999-06), 114-118 1121-189X 18:2<114 1999 18 EPS https://doi.org/10.1017/S1121189X00000993 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1017/S1121189X00000993 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Balestrieri Matteo Clinica di Psichiatria, Inter-University Centre for Behavioural Neurosciences, DPMSC, University of Udine, Udine NATIONALLICENCE 700 1- Sciascio Guido Di Azienda Universitaria Ospedale Policlinico, Bari NATIONALLICENCE 700 1- Isola Miriam Dipartimento di Ricerche Mediche e Morfologiche, University of Udine, Udine NATIONALLICENCE 700 1- Lomonaco Emanuele Struttura Complessa di Psichiatria, Dipartimento di Salute Mentale, ASL 12 Biella NATIONALLICENCE 700 1- Maso Elisa Clinica di Psichiatria, Inter-University Centre for Behavioural Neurosciences, DPMSC, University of Udine, Udine NATIONALLICENCE 700 1- Merli Roberto Struttura Complessa di Psichiatria, Dipartimento di Salute Mentale, ASL 12 Biella NATIONALLICENCE 700 1- Calò Salvatore Azienda Universitaria Ospedale Policlinico, Bari NATIONALLICENCE 700 1- Bellantuono Cesario Sezione di Psichiatria, Dipartimento di Neuroscienze, Università Politecnica delle Marche, Ancona NATIONALLICENCE 773 0- Epidemiologia e Psichiatria Sociale Cambridge University Press 18/2(1999-06), 114-118 1121-189X 18:2<114 1999 18 EPS CC0 http://creativecommons.org/publicdomain/zero/1.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-cambridge